List of Excipients in Branded Drug HEMABATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	HEMABATE	carboprost tromethamine	0009-0856	BENZYL ALCOHOL
Pharmacia & Upjohn Company LLC	HEMABATE	carboprost tromethamine	0009-0856	HYDROCHLORIC ACID
Pharmacia & Upjohn Company LLC	HEMABATE	carboprost tromethamine	0009-0856	SODIUM CHLORIDE
Pharmacia & Upjohn Company LLC	HEMABATE	carboprost tromethamine	0009-0856	SODIUM HYDROXIDE
Pharmacia & Upjohn Company LLC	HEMABATE	carboprost tromethamine	0009-0856	TROMETHAMINE

HEMABATE Excipient Strategy and Commercial Opportunities for Carboprost Tromethamine

Last updated: August 15, 2026

HEMABATE is a sterile injectable formulation of carboprost tromethamine, a prostaglandin F2α analogue used primarily for postpartum hemorrhage caused by uterine atony and for second-trimester abortion indications. The commercial opportunity is concentrated in generic or differentiated sterile-injectable products, supply reliability, packaging, stability, and hospital procurement rather than in new-molecule exclusivity.

The formulation is relatively simple compared with biologics or complex drug-delivery products. The main technical barriers are sterile manufacturing, low-dose uniformity, container-closure compatibility, stability, extractables and leachables, and validated cold-chain or controlled-storage performance. The principal commercial risks are limited procedure-driven demand, hospital price competition, manufacturing interruptions, and regulatory scrutiny over injectable quality.

What is HEMABATE and how is carboprost tromethamine formulated?

HEMABATE contains carboprost tromethamine, equivalent to 250 micrograms of carboprost per milliliter. It is supplied as a sterile solution for intramuscular injection. The product is administered in a clinical setting and is not a patient self-administration product.[1]

The formulation profile is consistent with a low-dose, aqueous, parenteral prostaglandin product:

Attribute	HEMABATE profile
Active ingredient	Carboprost tromethamine
Pharmacologic class	Prostaglandin F2α analogue
Strength	250 mcg/mL
Dosage form	Sterile injectable solution
Primary route	Intramuscular injection
Clinical settings	Obstetrics, postpartum hemorrhage, second-trimester abortion
Product type	Small-molecule drug product
Biosimilar pathway	Not applicable
Main regulatory pathway for competitors	ANDA or, in some cases, 505(b)(2)
Primary commercial buyers	Hospitals, health systems, group purchasing organizations, wholesalers

The approved product labeling identifies inactive formulation components and pH-adjusting agents. The exact excipient composition, manufacturing process, and container-closure system should be controlled against the current FDA-approved labeling and product-specific chemistry, manufacturing, and controls documentation.[1][2]

What excipients are used in HEMABATE?

HEMABATE uses a minimal excipient system suitable for a sterile aqueous injection. Public labeling identifies sodium chloride as a formulation excipient and indicates that pH is adjusted using sodium hydroxide and hydrochloric acid.[1]

Excipient functions

Excipient or processing component	Functional role	Commercial relevance
Sodium chloride	Tonicity adjustment	Supports injection tolerability and osmolality control
Sodium hydroxide	pH adjustment	Controls product pH during manufacture
Hydrochloric acid	pH adjustment	Fine-tunes final pH and supports batch consistency
Water for injection	Vehicle	Must meet compendial quality and bioburden requirements

The excipient strategy is not designed to provide prolonged release, enhanced absorption, or tissue targeting. Its purpose is to maintain a stable, sterile, injectable solution with acceptable osmolality and chemical purity.

For a generic applicant, the key issue is not simply matching the named excipients. The applicant must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. Differences in excipient concentration, pH, osmolality, preservative status, container closure, or impurity profile can affect the regulatory assessment even where the active ingredient and strength are unchanged.[3]

What formulation patents protect HEMABATE?

The commercial value of HEMABATE is unlikely to depend on an active formulation patent. Carboprost tromethamine is an established small molecule, and the original product approval dates back several decades. Any original compound, formulation, or use patents associated with the product would generally have expired long before the current market period.

The relevant protection layers are therefore:

1. Product-specific FDA approval and labeling.
2. Manufacturing know-how for sterile filling and impurity control.
3. Container-closure and packaging configurations.
4. Potentially distinct formulation patents held by later entrants.
5. Regulatory exclusivity, if any remains for a specific approved product or supplement.

Publicly available FDA resources should be checked for current Orange Book patent and exclusivity listings tied to the specific HEMABATE NDA. The product has no biologic exclusivity period, and the historical age of the product makes active new-drug exclusivity unlikely.[2][4]

Are there active Orange Book patents for HEMABATE?

HEMABATE should be evaluated as a legacy small-molecule product with limited likelihood of meaningful active Orange Book patent protection. The absence of a blocking patent does not eliminate regulatory or technical barriers. A generic applicant still must address:

• Pharmaceutical equivalence.
• Injectable-product sterility.
• Particulate matter.
• Bacterial endotoxins.
• Assay and degradation products.
• Container-closure integrity.
• Stability through the labeled storage period.
• Any listed method-of-use patents, if present.
• Appropriate labeling and contraindication language.

Orange Book status can change through patent-listing updates, product discontinuation codes, or changes in reference-listed-drug designation. A transaction or launch decision should rely on the current FDA Orange Book record rather than historical patent summaries.[4]

When does HEMABATE lose exclusivity?

HEMABATE's principal market exclusivity is already historical rather than prospective. The product was approved many years ago, so the commercial question is generic competition and supply execution, not loss of a near-term patent estate.

Exclusivity category	HEMABATE assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable to the core product
Biologic exclusivity	Not applicable
Pediatric exclusivity	No meaningful current barrier identified
Original patent term	Expected to have expired
Current commercial protection	Brand recognition, procurement relationships, manufacturing capability, and supply reliability

The absence of active exclusivity creates a relatively open market for ANDA applicants. It also limits the value of licensing a legacy product unless the transaction includes manufacturing capacity, hospital contracts, or rights to a differentiated presentation.

What generic entry risks exist for HEMABATE?

Generic entry risk is high from a legal perspective but more complex operationally. The drug has an established clinical role and a conventional injectable presentation, which supports ANDA development. At the same time, sterile injectables have higher manufacturing and inspection risk than many oral solid products.

Paragraph IV challenges

A Paragraph IV certification is relevant only if the reference product has an unexpired Orange Book-listed patent. Given the age of HEMABATE, a Paragraph IV challenge is unlikely to be the central barrier unless a later-listed patent covers a specific formulation, container, or method of use.

A generic applicant may instead rely on Paragraph III or certification that no relevant patent is listed. The practical launch timeline would then depend on ANDA approval, manufacturing readiness, FDA inspection outcomes, and any commercial settlement or supply agreement.

Generic launch scenarios

Scenario	Likely market effect
One approved generic with reliable supply	Moderate price erosion and rapid hospital conversion
Multiple approved generics	Significant tender and GPO price pressure
Brand supply interruption	Temporary share gains for available competitors
Generic manufacturing warning letter or recall	Rapid reallocation to other approved suppliers
Differentiated packaging or ready-to-use presentation	Potential premium in hospital procurement
New route or extended-stability formulation	Higher regulatory burden but possible niche pricing

The most valuable competitive advantage is likely to be consistent supply rather than a minor excipient change.

What excipient innovations could create commercial opportunities?

The baseline formulation leaves several possible development paths, although each requires a clear clinical or procurement benefit.

Preservative-free unit-dose presentation

A preservative-free, single-dose vial or prefilled syringe could reduce preparation steps and concerns about preservative exposure. The opportunity is strongest in emergency obstetric settings where rapid administration and error reduction have procurement value.

The development burden includes syringe compatibility, silicone-oil assessment, extractables and leachables, plunger interaction, needle selection, and container-closure integrity.

Ready-to-use prefilled syringe

A prefilled syringe could reduce dose preparation time for the 250 mcg/mL strength. Commercial value would depend on hospital pharmacy economics, storage requirements, compatibility with existing emergency carts, and whether the syringe can withstand distribution and handling without leakage or dose loss.

Improved low-temperature or room-temperature stability

A formulation or packaging system with robust stability under short-term temperature excursions could help hospitals and wholesalers manage inventory. Any such claim must be supported by formal stability studies and would not automatically qualify for labeling without FDA review.

Potential approaches include:

• Optimized pH control.
• Low-peroxide excipients and manufacturing materials.
• Improved oxygen control during filling.
• Light-protective packaging.
• Enhanced container-closure systems.
• Reduced headspace oxygen.

Alternative container systems

Glass ampules, single-dose vials, cartridges, and prefilled syringes create different risk profiles. The best commercial choice depends on breakage, particulate risk, filling-line compatibility, automation, and hospital workflow.

A polymer container could improve handling but may raise concerns about adsorption, permeation, extractables, and leachables. Glass may provide stronger chemical familiarity but can increase breakage and particulate-control requirements.

Excipient substitution

Excipient substitution alone is unlikely to support a strong premium unless it produces a measurable benefit. A different tonicity agent, buffering system, or stabilizer could trigger additional comparability work and raise regulatory questions. The strongest rationale would be:

• Better stability.
• Lower impurity formation.
• Improved tolerability.
• Reduced container interaction.
• Compatibility with a prefilled device.
• Removal of a component that creates procurement or safety concerns.

What manufacturing and intellectual-property barriers affect HEMABATE competitors?

The manufacturing barrier is more significant than the composition-of-matter patent barrier. Carboprost tromethamine injection requires controlled sterile production at a low dose, where small deviations can affect content uniformity and impurity limits.

Key manufacturing risks include:

• Sterile filtration and aseptic filling.
• Validation of hold times.
• Control of bioburden and endotoxins.
• Accurate low-dose filling.
• Degradation-product monitoring.
• Container-closure integrity.
• Particulate matter control.
• Stability after manufacture.
• Reliable access to qualified API.
• FDA inspection readiness.

Potential intellectual-property positions for a new entrant could include a prefilled device, a specific container-closure system, a stabilizing formulation, a manufacturing process, or an extended-stability profile. Such patents would protect a differentiated product, not the underlying carboprost molecule.

Freedom-to-operate analysis should cover U.S., European, Canadian, and major emerging-market rights. Patent expiry in one country does not establish freedom to operate elsewhere. The most relevant jurisdictions are those with substantial obstetric hospital markets and established sterile-injectable manufacturing.

What is the FDA regulatory status of HEMABATE?

HEMABATE is an FDA-approved prescription injectable product. Its FDA-approved indications include routine management of postpartum hemorrhage due to uterine atony that has not responded to conventional management and selected second-trimester abortion indications.[1]

The product is regulated as a small-molecule drug, not a biologic. A competitor would generally pursue an ANDA if it can demonstrate equivalence to the reference product. A 505(b)(2) application could be relevant for a materially different presentation, route, dosing regimen, or formulation where the applicant cannot rely fully on the reference product's findings.

The label contains important contraindications and warnings, including asthma, active pulmonary disease, cardiovascular, renal, or hepatic disease, and hypersensitivity. A commercial entrant must preserve required safety information while ensuring that any device, packaging, or formulation change does not create labeling inconsistency.[1]

How does HEMABATE compare with competing postpartum hemorrhage products?

HEMABATE competes with other uterotonic therapies, but the products are not interchangeable in clinical use.

Product	Active ingredient	Common formulation	Main commercial distinction
HEMABATE	Carboprost tromethamine	250 mcg/mL injection	Prostaglandin analogue; useful when uterine atony persists
Oxytocin products	Oxytocin	Injectable solution	Common first-line uterotonic
Methylergonovine products	Methylergonovine maleate	Injectable or oral forms	Alternative uterotonic with cardiovascular restrictions
Misoprostol products	Misoprostol	Oral, buccal, sublingual, or rectal use depending on practice	Room-temperature solid dosage form and flexible administration
Tranexamic acid	Tranexamic acid	Injectable or oral	Antifibrinolytic, not a uterotonic

HEMABATE's commercial position is strongest where clinicians need a potent injectable uterotonic and where alternative agents are unsuitable or ineffective. Its limitations include adverse-effect concerns, contraindications in patients with asthma or pulmonary disease, and the need for trained clinical administration.

Which companies are challenging or supplying HEMABATE?

The relevant competitive set consists of the brand manufacturer, approved generic injectable manufacturers, contract sterile-fill organizations, and suppliers with hospital or GPO access. Supplier identity, approval status, and market availability should be verified through current FDA listings, DailyMed records, wholesaler data, and procurement databases.[2][5]

The competitive landscape is vulnerable to supply concentration. A small number of sterile-injectable suppliers can create temporary shortages when one manufacturer experiences a quality event, inspection issue, API disruption, or filling interruption. That dynamic can create commercial opportunity for a secondary supplier with validated capacity and a strong shortage-response record.

What revenue exposure and licensing opportunities exist?

HEMABATE's revenue exposure is tied to hospital utilization rather than broad retail demand. The principal value drivers are:

• Number of obstetric hospitals served.
• Contract position with GPOs.
• Wholesaler inventory.
• Product availability during shortage periods.
• Unit-dose and prefilled-device economics.
• Generic price erosion.
• Manufacturing cost per dose.
• API supply security.

Licensing opportunities are more likely to involve commercial infrastructure than molecule rights. Potential transactions include:

1. Acquisition of an approved ANDA.
2. In-licensing of a sterile injectable manufacturing process.
3. Contract manufacturing with a qualified aseptic facility.
4. Co-development of a prefilled syringe.
5. Regional distribution rights.
6. Supply agreements with hospital systems.
7. Portfolio bundling with oxytocin, methylergonovine, or tranexamic acid.

A license limited to carboprost rights would have low strategic value unless it includes an approved product, reliable manufacturing capacity, or a protected presentation.

How strong is the HEMABATE patent estate?

The patent estate is weak as a barrier to generic entry because the underlying drug and original product approval are old. The defensible value lies in execution:

• FDA-compliant sterile production.
• Stable supply.
• Device and packaging differentiation.
• Hospital procurement access.
• Manufacturing know-how.
• Regional registrations.
• Quality systems and regulatory history.

For investment or licensing purposes, HEMABATE should be analyzed as a mature injectable product with operational scarcity value, not as a product protected by a substantial remaining patent term.

Key Takeaways

• HEMABATE is a 250 mcg/mL sterile carboprost tromethamine injection.
• Its formulation uses a limited excipient system centered on sodium chloride, water for injection, and pH adjustment.
• Original molecule and product exclusivity are historical; current value is unlikely to depend on an active patent estate.
• Generic entry risk is high, although sterile manufacturing and FDA quality requirements remain meaningful barriers.
• The strongest product opportunities are preservative-free unit doses, prefilled syringes, improved stability, and reliable hospital supply.
• Excipient substitution alone is unlikely to command a premium without a measurable stability, safety, or workflow benefit.
• Biosimilar competition is not relevant because carboprost tromethamine is a small-molecule drug.
• Licensing value is concentrated in approved regulatory assets, sterile capacity, packaging technology, and hospital distribution.

FAQs

Can carboprost tromethamine be developed as an oral tablet?

An oral product would not be a straightforward generic equivalent to HEMABATE. It would likely require a different regulatory strategy, new pharmacokinetic and clinical evaluation, and a separate commercial rationale.

Does HEMABATE require refrigeration?

Storage requirements must follow the current FDA-approved labeling and product-specific package insert. A competitor cannot assume that a revised excipient system has the same storage profile without supporting stability data.

Is a prefilled HEMABATE syringe automatically substitutable with the vial?

No. A prefilled syringe may require separate regulatory assessment, device compatibility testing, labeling review, and a determination of whether it is therapeutically and pharmaceutically equivalent to the reference presentation.

Could a new carboprost formulation obtain new patent protection?

Yes. A novel formulation, device, container-closure system, manufacturing process, or stability profile may support patent protection if it satisfies applicable novelty and non-obviousness standards. Such protection would cover the new feature rather than the carboprost molecule itself.

What is the most attractive commercial strategy for a HEMABATE competitor?

The strongest strategy is a reliable, FDA-compliant sterile injectable with differentiated packaging or workflow benefits, supported by dependable API sourcing and hospital procurement access. A composition-only generic is more exposed to price competition.

References

1. U.S. Food and Drug Administration. (n.d.). HEMABATE carboprost tromethamine injection prescribing information. Pfizer Laboratories.

2. National Library of Medicine. (n.d.). DailyMed: HEMABATE carboprost tromethamine injection. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2013). ANDA submissions: Content and format of abbreviated new drug applications. https://www.fda.gov/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

5. U.S. Food and Drug Administration. (n.d.). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/